10x Genomics today announced a multi-year collaboration with Dana-Farber Cancer Institute to perform single cell and spatial profiling on tumor samples from several hundred patients across major solid tumor types. Using Chromium Flex single cell assays and Xenium spatial platforms, the teams will generate integrated cellular and spatial maps linked to known clinical outcomes for therapies such as antibody-drug conjugates, radioligand treatments, bispecific antibodies and checkpoint inhibitors. By analyzing treatment responders versus non-responders, the initiative aims to pinpoint predictive biomarkers and microenvironmental features—such as immune cell infiltration patterns or target expression gradients—that correlate with response, resistance and disease progression. This effort seeks to define a standardized clinical reporting framework for precision oncology laboratories and inform therapy selection based on high-resolution tumor biology rather than bulk assays alone.

In parallel with the Dana-Farber study, 10x Genomics plans to establish a CLIA-certified laboratory in Pleasanton, California, to support assay implementation, analytical validation and clinical sample processing. The lab build-out will include instrumentation for both single cell and spatial workflows, quality management systems and procedural documentation designed to meet regulatory requirements. This facility will enable 10x to offer investigational diagnostic services and serve as a development hub for future in vitro diagnostic tests leveraging single cell resolution. According to management, the CLIA lab marks the first step toward transitioning research-grade workflows into regulated diagnostics, positioning the company to collaborate with academic and biopharma partners in bringing next-generation precision oncology assays to clinical practice.